Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer

Journal of Clinical Oncology

Volumn 29, Issue 31, 2011, Pages 4160-4167

  Kim, Chungyeul ^a   Tang, Gong ^a,b   Pogue Geile, Katherine L ^a   Costantino, Joseph P ^a,b   Baehner, Frederick L ^e,f   Baker, Joffre ^e   Cronin, Maureen T ^e   Watson, Drew ^e   Shak, Steven ^e   Bohn, Olga L ^a   Fumagalli, Debora ^a   Taniyama, Yusuke ^a   Lee, Ahwon ^a   Reilly, Megan L ^a   Vogel, Victor G ^a,d   McCaskill Stevens, Worta ^g   Ford, Leslie G ^g   Geyer Jr , Charles E ^a,c   Wickerham, D Lawrence ^a,c   Wolmark, Norman ^a,c   Paik, Soonmyung ^a   more..

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d GEISINGER HEALTH SYSTEM   (United States)

^e Genomic Health   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PLACEBO; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RESISTANCE; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DOWN-REGULATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LINEAR MODELS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN ARRAY ANALYSIS; RETROSPECTIVE STUDIES; RNA, MESSENGER; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80755155720     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.9615     Document Type: Article

References (20)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: An overview of the randomized trials. Lancet 365:1687-1717, 2005
2. Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998 (Pubitemid 28439961)
3. Clarke R, Liu MC, Bouker KB, et al.: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316- 7339, 2003
4. Bryant J, Fisher B, Gunduz N, et al.: S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 51:239-253, 1998 (Pubitemid 29054557)
5. Fisher B, Redmond C, Brown A, et al.: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1:227-241, 1983 (Pubitemid 14189661)
6. McGuire WL: Estrogen receptors in human breast cancer. J Clin Invest 52:73-77, 1973
7. Morgan LR Jr, Schein PS, Woolley PV, et al.: Therapeutic use of tamoxifen in advanced breast cancer: Correlation with biochemical parameters. Cancer Treat Rep 60:1437-1443, 1976 (Pubitemid 8055856)
8. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004 (Pubitemid 40051905)
9. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989 (Pubitemid 19062522)
10. Fisher B, Jeong JH, Bryant J, et al.: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. Lancet 364:858-868, 2004
11. Gray RJ: Spline-based tests in survival analysis. Biometrics 50:640-652, 1994
12. Harvey JM, Clark GM, Osborne CK, et al.: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999 (Pubitemid 29220854)
13. Esseghir S, Todd SK, Hunt T, et al.: A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. Cancer Res 67:11732-11741, 2007
14. Collins LC, Botero ML, Schnitt SJ: Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: An analysis of 825 cases. Am J Clin Pathol 123:16-20, 2005 (Pubitemid 40066167)
15. Paik S, Tang G, Shak S, et al.: Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006 (Pubitemid 46622311)
16. Dowsett M, Allred C, Knox J, et al.: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 26:1059-1065, 2008
17. De Placido S, De Laurentiis M, Carlomagno C, et al.: Twenty-year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9:1039-1046, 2003 (Pubitemid 36323709)
18. Dowsett M, Houghton J, Iden C, et al.: Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor, and HER2 status. Ann Oncol 17:818-826, 2006
19. Ellis MJ, Coop A, Singh B, et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001 (Pubitemid 32880059)
20. Konecny G, Pauletti G, Pegram M, et al.: Quantitative association between HER-2/neu and steroid receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142-153, 2003 (Pubitemid 36193263)